Company / Capital Expenditures
Black Diamond Therapeutics, Inc. Capital Expenditures History
FY2019-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$142.0K
FY2020
5-year range
$21.0K / $142.0K
FY2019-FY2020
Trend
+576.2%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$142,000 in FY2020.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, capital expenditures increased 576.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.60 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $142.0K | +576.2% |
| FY2019 | $21.0K | - |
As of FY2020 · SEC Form 10-K · Last checked Jun 21, 2026